Pegylated liposomal doxorubicin monotherapy (Kaposi sarcoma)
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
Registro de base de conhecimento para auditoria. Conteúdo clínico provisório: não é uma prescrição. Um oncologista deve verificar fontes originais, aplicabilidade e estado de revisão. Regras completas e restrições estão no YAML.
| Componentes | DRUG-PEGYLATED-LIPOSOMAL-DOXORUBICIN |
|---|
| ID | REG-PLD-KAPOSI |
|---|---|
| Tipo | Esquema terapêutico |
| Estado | reviewed 2026-07-11 | pending_clinical_signoff |
| Doenças | Nenhuma declaração |
| Fontes | Nenhuma declaração |
Notas
New Regimen entity reusing the existing DRUG-PEGYLATED-LIPOSOMAL- DOXORUBICIN Drug entity. The 20 mg/m² IV q2-3wk Kaposi sarcoma dose and toxicity-management triggers (hold thresholds for PPE, stomatitis, ANC/platelet nadir, LVEF decline) are transcribed directly from that ALREADY-EXISTING Drug entity's `typical_dosing`/`notes` fields (which independently document "Kaposi sarcoma: 20 mg/m² IV every 2-3 weeks" and the hold criteria -- verified by direct read of drugs/pegylated_liposomal_doxorubicin.yaml during independent review) -- not a newly invented figure. Pegylated liposomal doxorubicin is FDA-approved for AIDS-related Kaposi sarcoma (see DRUG-PEGYLATED-LIPOSOMAL-DOXORUBICIN.regulatory_status.fda. indications_brief). INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 throughout this file (top-level sources, every dose-adjustment, every watchpoint) as the evidentiary support for the dosing/toxicity-management content above. Direct inspection of that source's own KB record (sources/src_nccn_skin_2025.yaml) shows its title is "NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer" and its notes explicitly scope it to basal-cell...
Usado por
Doença
DIS-KAPOSI- Sarcoma de Kaposi
Indicação
IND-KAPOSI-1L-VISCERAL-PLD- IND-KAPOSI-1L-VISCERAL-PLD